SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055069
Filing Date
2024-05-08
Accepted
2024-05-08 07:30:33
Documents
73
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20240331.htm   iXBRL 10-Q 2023074
2 EX-31.1 verv-ex31_1.htm EX-31.1 15640
3 EX-31.2 verv-ex31_2.htm EX-31.2 15726
4 EX-32.1 verv-ex32_1.htm EX-32.1 8952
5 EX-32.2 verv-ex32_2.htm EX-32.2 8876
  Complete submission text file 0000950170-24-055069.txt   7633668

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT verv-20240331.xsd EX-101.SCH 1302149
77 EXTRACTED XBRL INSTANCE DOCUMENT verv-20240331_htm.xml XML 1071973
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 24924257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)